House Panel Demands More Information From Mylan In Light Of Tax Omissions
Committee leaders have asked for documents including all of those related to EpiPen sales, profits, costs, manufacturing and distribution of the product; to the CEO's preparation for the committee hearing; documents about Mylan’s tax rates since 2007; and more.
The Wall Street Journal:
House Committee Taps Mylan For More Information On EpiPen Price Figures
A U.S. House committee sent a letter to Mylan NV demanding a fuller explanation of why the company omitted key information that it used to calculate the profit figure for the lifesaving EpiPen drug that its chief executive provided during a congressional hearing last month. ... House committee leaders, in a letter to Ms. Bresch dated Sept. 30 and released Monday, said her testimony “omitted key tax assumptions that affect the company’s profit per pack.” They said the omission ”raises questions.” (Loftus, 10/3)
In other pharmaceutical news —
CVS Pushed Out Of Tricare Pharmacy Network
In a blow to CVS Health Corp., pharmacy benefit manager Express Scripts Holding Co. announced it has ousted the provider from the pharmacy network it manages for Tricare, the U.S. Defense Department's health benefits program with 9.4 million beneficiaries. (Livingston, 10/3)